The U.S. Patent and Trademark Office (USPTO) is granting a patent for Rezdiffra (resmetirom) — Madrigal Pharmaceuticals’ approved therapy for metabolic dysfunction-associated steatohepatitis (MASH),…
In infants younger than 3 months, identifying heart problems and distinctive facial features, as well as blood markers and certain liver tissue abnormalities, may aid…
Access to hepatitis C treatment and care remains low among children and recently pregnant women in the U.S., according to data from two recently…
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Severe intrahepatic cholestasis of pregnancy (ICP) significantly raises the risks of adverse outcomes in twin pregnancies, according to a single-center, retrospective study conducted in…
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
Throughout July, the nonprofit Biliary Atresia Research & Education (BARE) is holding its Live and Let Live(r) fundraising campaign to raise money and awareness…
BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…
Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…
